DE602005015834D1 - 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus - Google Patents

3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus

Info

Publication number
DE602005015834D1
DE602005015834D1 DE602005015834T DE602005015834T DE602005015834D1 DE 602005015834 D1 DE602005015834 D1 DE 602005015834D1 DE 602005015834 T DE602005015834 T DE 602005015834T DE 602005015834 T DE602005015834 T DE 602005015834T DE 602005015834 D1 DE602005015834 D1 DE 602005015834D1
Authority
DE
Germany
Prior art keywords
prolin
hepatitis
cyclopentyl
virus
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005015834T
Other languages
German (de)
English (en)
Inventor
George F Njoroge
Srikanth Venkatraman
Ashok Arasappan
Francisco Velazquez
Viyyoor M Girijavallabhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602005015834D1 publication Critical patent/DE602005015834D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DE602005015834T 2004-02-27 2005-02-24 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus Expired - Lifetime DE602005015834D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54865504P 2004-02-27 2004-02-27
PCT/US2005/005778 WO2005087730A1 (en) 2004-02-27 2005-02-24 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease

Publications (1)

Publication Number Publication Date
DE602005015834D1 true DE602005015834D1 (de) 2009-09-17

Family

ID=34961939

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015834T Expired - Lifetime DE602005015834D1 (de) 2004-02-27 2005-02-24 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus

Country Status (11)

Country Link
US (1) US7342041B2 (enExample)
EP (1) EP1737821B1 (enExample)
JP (1) JP2007525512A (enExample)
CN (1) CN1946692A (enExample)
AR (1) AR048413A1 (enExample)
AT (1) ATE438622T1 (enExample)
CA (1) CA2557307A1 (enExample)
DE (1) DE602005015834D1 (enExample)
ES (1) ES2328589T3 (enExample)
TW (1) TWI302835B (enExample)
WO (1) WO2005087730A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
ITRE20010042A1 (it) * 2001-04-24 2002-10-24 Corghi Spa Dispositivo sollevatore per macchine smontagomme
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
CN1946718A (zh) * 2004-02-27 2007-04-11 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的具有环p4′s的新型酮酰胺
CN1946691A (zh) * 2004-02-27 2007-04-11 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
JP5160415B2 (ja) * 2005-06-02 2013-03-13 メルク・シャープ・アンド・ドーム・コーポレーション 医薬処方物およびそれを用いる治療方法
CN101263156A (zh) 2005-07-25 2008-09-10 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
PT1934179E (pt) * 2005-08-19 2010-07-12 Vertex Pharma PROCESSOS E INTERMEDIáRIOS
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
CN101415705B (zh) 2005-10-11 2011-10-26 因特蒙公司 抑制丙型肝炎病毒复制的化合物和方法
JP5409008B2 (ja) 2005-11-11 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス改変体
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
WO2007083620A1 (ja) * 2006-01-20 2007-07-26 Kaneka Corporation β－アミノ－α－ヒドロキシ酸アミド誘導体の製造法
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP2009132621A (ja) * 2006-03-13 2009-06-18 Ajinomoto Co Inc シクロプロピルアミド化合物の製造方法
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
US20070265281A1 (en) * 2006-04-11 2007-11-15 Sylvain Cottens Organic Compounds and Their Uses
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
WO2007133865A2 (en) * 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors an their uses
EP2039689A4 (en) 2006-05-26 2011-12-28 Kaneka Corp PROCESS FOR PREPARING OPTICALLY ACTIVE 3-AMINO-2-HYDROXYPROPIONIC ACID CYCLOPROPYLAMID DERIVATIVES AND SALTS THEREOF
DE102006059317A1 (de) * 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CA2660555A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
BRPI0807907A2 (pt) 2007-02-27 2017-05-16 Vertex Pharma co-cristais e composições farmacêuticas compreendendo os mesmos.
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
EP2160392A2 (en) * 2007-05-03 2010-03-10 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2008141227A1 (en) 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
TW200922933A (en) 2007-08-30 2009-06-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
AU2008309589B2 (en) * 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
EP2215076A4 (en) * 2007-10-24 2012-05-02 Virobay Inc COMPOUNDS CAPABLE OF INHIBITING CATHEPSIN S PROTEASE AND HCV REPLICATION
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
BRPI0911260A2 (pt) 2008-04-15 2015-09-29 Intermune Inc composto, composição farmacêutica, método de inibição de atividade da protease de ns3/ns4 in, vitro e usos de compostos
MX2010014500A (es) * 2008-06-24 2011-05-30 Codexis Inc Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros.
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
AR080676A1 (es) 2010-03-09 2012-05-02 Schering Corp Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
EP2707346A1 (en) * 2011-05-13 2014-03-19 Vertex Pharmaceuticals Inc. Process for the preparation of protease inhibitors
CN103814001A (zh) * 2011-05-13 2014-05-21 弗特克斯药品有限公司 方法和中间体
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
AR091192A1 (es) 2012-05-30 2015-01-21 Chemo Iberica Sa Procedimiento multicomponente para la preparacion de compuestos biciclicos
CN103508918B (zh) * 2012-06-18 2015-09-09 上海医药工业研究院 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法
ITMI20122205A1 (it) * 2012-12-20 2014-06-21 Dipharma Francis Srl Sintesi di un intermedio di un inibitore delle proteasi virali
CN103387510B (zh) * 2013-08-08 2015-09-09 苏州永健生物医药有限公司 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
CN103664739B (zh) * 2013-12-10 2016-04-27 湖南科源生物制品有限公司 一种特拉匹韦中间体的制备方法
CN104926712B (zh) * 2014-03-20 2018-03-23 上海医药工业研究院 合成特拉匹韦的中间体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co. Ltd., Tokio/Tokyo Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
US5371017A (en) 1990-04-04 1994-12-06 Chiron Corporation Hepatitis C virus protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
JP2000256396A (ja) 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
EP1268519B1 (en) 2000-04-03 2005-06-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
DE60137207D1 (de) 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
SK14952002A3 (sk) 2000-04-19 2003-03-04 Schering Corporation Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
RU2355700C9 (ru) 2000-07-21 2010-03-20 Шеринг Корпорейшн Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
NZ523781A (en) 2000-07-21 2004-10-29 Corvas Int Inc Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
HUP0303436A2 (hu) 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US7456629B2 (en) 2006-07-11 2008-11-25 Continental Automotive Systems Us, Inc. Rotary angle sensing system

Also Published As

Publication number Publication date
EP1737821B1 (en) 2009-08-05
CN1946692A (zh) 2007-04-11
JP2007525512A (ja) 2007-09-06
TWI302835B (en) 2008-11-11
HK1095820A1 (en) 2007-05-18
AR048413A1 (es) 2006-04-26
US20050197301A1 (en) 2005-09-08
ATE438622T1 (de) 2009-08-15
WO2005087730A1 (en) 2005-09-22
US7342041B2 (en) 2008-03-11
TW200536530A (en) 2005-11-16
CA2557307A1 (en) 2005-09-22
ES2328589T3 (es) 2009-11-16
EP1737821A1 (en) 2007-01-03

Similar Documents

Publication Publication Date Title
DE602005015834D1 (de) 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005021760D1 (de) Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
ATE434621T1 (de) Neue verbindungen als inhibitoren der ns3- serinprotease des hepatitis-c-virus
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
DE602005015452D1 (de) Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
ATE514691T1 (de) Neue ketoamide mit cyclischen p4 als inhibitoren der ns3-serinprotease von hepatitis-c-virus
WO2001074768A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE60332814D1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
ATE461209T1 (de) Hcv ns-3 serine protease inhibitoren
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
EP2125870A4 (en) INHIBITORS OF HEPATITIS C NS3 PROTEASE
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
ATE435211T1 (de) Imidazolidinone als ns3-serin protease inhibitoren von hepatitis c virus
EA200800670A1 (ru) Ингибиторы сериновых протеаз
NO20030271D0 (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C- virus
WO2006119061A3 (en) Hcv ns3 protease inhibitors
WO2006086381A3 (en) Hepatitis c virus inhibitors
HK1097528A (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
DK1268519T3 (da) Inhibitorer af serinproteaser, især hepatitis C-virus NS3-protease
HK1096657A (en) Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
HK1097262A (en) Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease
HK1097261A (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition